来源:[1] 赛诺菲(ENXTPA:SAN)在突破性罕见疾病疗法获FDA批准后的估值展望 (https://finance.yahoo.com/news/look-sanofi-en ...)[2] 赛诺菲Wayrilz:罕见血液疾病BTK抑制剂市场的战略突破 - AInvest (https://vertexaisearch.cloud.google.com/groun ...)[3] 赛诺菲Wayrilz:罕见疾病和免疫学市场的颠覆者 - AInvest (https://ainvest.com/sanofis-wayrilz-a-game-ch ...)